China In-Depth
Help your business succeed in the lucrative Chinese pharmaceutical market through DRG’s China In-Depth comprehensive data and insights. Assess commercial opportunities and optimize your strategy in China for nearly twenty key indications:
China In-Depth 2020 Coverage
- Acute Myeloid Leukemia
- NSCLC
- Hepatitis B Virus
- Psoriasis
- Heart Failure
- Non-Hodgkin’s Lymphoma
- Breast Cancer
- Migraine
- Gastric Cancer
- Colorectal Cancer
- Prostate Cancer
- Atopic Dermatitis
- Biosimilars in China
China In-Depth 2019 Coverage
- Non-Small Cell Lung Cancer
- Hepatocellular Carcinoma
- Rheumatoid Arthritis
- Non-Alcoholic Fatty Liver Disease
- Multiple Sclerosis
- Type 2 Diabetes
- Gastric Cancer
- Colorectal Cancer
- Bladder Cancer

We have prioritized these indications based on China’s epidemiology landscape, clinical unmet needs, and commercial opportunities. Our solution features broad, deep, and geographically diverse primary market research with five thought-leading physician interviews and 50 physician surveys per indication.